CITCO 2.0
CITCO extended for an additional five years (2025鈥�2029)
CITCO was established in 2020 as a close collaboration between researchers and clinicians from the Clinical Immunology Department and the Hematology Department at Odense University Hospital (OUH). CITCO successfully passed its four-year evaluation by the OUH Research Council in February 2024.
The research center has been a significant success, achieving a milestone in November 2023 by performing Denmark's first CAR-T therapy on a patient with bone marrow cancer (multiple myeloma). Since then, more than ten patients have been treated with CAR T cells at OUH. Another key milestone has been the establishment of what may be Denmark's best GMP/GMO-2 production facility on St忙rmoseg氓rdsvej in Odense. As a result, the OUH management has decided to allocate an additional 14 million DKK to allow the elite research center to continue for another five years (2025鈥�2029).
"The continuation of CITCO is a huge recognition of CITCO's talented staff and will lead to more innovative treatments for cancer and other serious diseases in the years to come", says Torben Barington, CITCO's leader.